pharmaphorum
AUGUST 17, 2020
Sanofi’s acquisition builds on a partnership to develop central nervous system drugs that began in late 2017. In a statement Sanofi said that the acquisition will give it full control of the brain-penetrant BTK inhibitor, SAR442168, making marketing more efficient and eliminating any royalty payments due under the 2017 agreement.
pharmaphorum
JUNE 1, 2021
Patients will also receive a dose of tacrolimus, an immune-suppressing drug, to guard against any immune reaction to the transplanted cells. The hope is that the spheroids will help to replenish damaged cardiomyocytes in the heart, restoring some of its ability to pump blood around the body. Other readouts give grounds for optimism.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
ALiEM - Pharm Pearls
DECEMBER 18, 2023
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): An Interplay among Drugs, Viruses, and Immune System. 2017 Jun 9;18(6):1243. Corticosteroids are the mainstay of treatment with gradual tapering over multiple months. References Cho YT, Yang CW, Chu CY. Int J Mol Sci. doi: 10.3390/ijms18061243.
Pharmaceutical Technology
JUNE 12, 2023
CB1 is predominantly found in the central and peripheral nervous system, whereas CB2 is primarily located in immune cells. However, 2017 saw the discontinuation of nabiximols from Phase III development in the US for cancer pain, due to lack of efficacy.
pharmaphorum
MARCH 24, 2022
There’s a rich history of finding useful medicines from fungi, from the antibiotic penicillin to immune suppressant cyclosporine and cholesterol drug lovastatin. The examples remain few and far between, however, as in recent decades the pharma industry has turned its attention to synthetic molecules and biologics like antibodies.
LifeProNow
APRIL 11, 2023
Nirsevimabhas been developed to offer newborns and infants direct RSV protection via an antibody to help prevent lower respiratory tract disease (LRTD) caused by RSV.Monoclonal antibodies do not require the activation of the immune system to help offer timely, rapid and direct protection against disease.
European Pharmaceutical Review
JANUARY 26, 2023
CAR T-cell therapy engineers a patient’s own immune cells (T-cells) to detect, target and destroy cancer cells. Of those who receive a transplant, about 50 percent will ultimately relapse, stated research from 2017, published in the journal Blood. Could CAR T therapies be manufactured in one day?
Expert insights. Personalized for you.
124 
Let's personalize your content